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Summary
In this paper, we report a case of a 57-year-old male patient with non-metastatic dorso-lumbar glioblastoma multi-
forme (GBM) who underwent total cordectomy followed by chemoradiotherapy. Primary dorso-lumbar GBM is a rare find-
ing. Despite the total cordectomy and chemoradiotherapy treatment, recurrence occurs mostly within a short time with poor 
prognosis.
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TOTALNA KORDEKTOMIJA U PACIJENTA S PRIMARNIM DORZOLUMBARNIM MULTIFORMNIM  
GLIOBLASTOMOM I PARAPLEGIJOM – PRIKAZ SLUČAJA
Sažetak
Muškarac u dobi od 57 godina s nemetastatskim multiformnim dorzolumbalnim glioblastomom (GBM) podvrgnut je 
totalnoj kordektomiji i kemoradioterapiji. Primarni dorzolumbalni GBM se rijetko nalazi. Unatoč totalnoj kordektomiji i 
kemoradioterapiji bolest se vraća s lošom prognozom u kratkom vremenskom razdoblju.
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INTRODUCTION
In adults, the most common malignant pri-
mary brain tumor is glioblastoma multiforme 
(GBM) (1). On the spinal level, GBM represents a 
minority of all spinal cord tumors and only 7.5% 
of all intramedullary gliomas (2), with few studies 
reporting intracranial dissemination (3). In 60% of 
spinal GBM cases, the tumor was detected in cer-
vical or cervicothoracic regions, indicating that 
these regions are the most common sites for spinal 
GBM (4). In contrast to supratentorial GBM, spinal 
glioblastoma (GB) is usually present during the 
second and third decades of life (5). However, ce-
rebral and spinal GB are similar in terms of histo-
pathological features (6). Although most spinal 
GBM cases experienced short-term survival, some 
cases experienced long-term survival of over 18 
months (6). We report here a patient with non-
metastatic dorso-lumbar GBM who underwent 
total cordectomy followed by chemoradiotherapy 




A 57-year-old male had a progressive motor 
weakness of both lower limbs and was mobile 
with the aid of a cane. The patient also had hyper-
tension and had been previously treated with so-
fosbuvir for hepatitis C virus (HCV). In June 2016, 
he was referred to our clinic in Kasr Al Aini Hos-
pital with magnetic resonance (MR) imaging of 
the thoracolumbar vertebra showing only spon-
dylodegenerative changes in L4-L5 disc.
In December 2016, the condition progressed 
as the patient developed urine and stool inconti-
nence. Moreover, the neurological examination 
revealed worsening of motor functions with weak-
ness of both lower limbs grade 1 (with the patient 
confined to a wheelchair) and jacket sensory loss 
at the lower dorsal level with no neurologic abnor-
mality of the upper limbs. Accordingly, MRI dor-
so-lumbar spine with contrast revealed intramed-
ullary mass lesion with low T1 and intermediate 
T2 signal intensity and rather heterogeneous con-
trast enhancement; this lesion was confined to 
level T11–L1 with compression of conus medul-
laris (CM), causing fusiform expansion of the cord 
(Figure 1). Workup for extra-neuronal metastases 
was done including post-contrast computed to-
mography (CT) scan of the chest, non-contrast CT 
abdomen, and pelvis, 99mTc with methylene di-
phosphonate (TC-MDP) bone scan, in addition to 
MR brain with contrast and all of them were nega-
tive. In December 2016, the patient underwent to-
tal cordectomy for the tumor. An irregular greyish 
red mass measuring 5x5 cm was sent for histopa-
thology, which revealed the following results 
Figure 1: MR dorso-lumbar spine 
with contrast sagittal T1, showing 
intramedullary mass lesion (arrow) 
with low T1 and intermediate T2 
signal intensity and rather heterog-
enous contrast enhancement, con-
fined to level T11–L1 with compres-
sion of conus medullaris.
Figure 2: (a) astrocytes with moderate nuclear polymorphism 
(un-circled arrows) scattered within the eosinophilic fibrillary 




(Figure 2): astrocytes with moderate nuclear poly-
morphism were scattered within the eosinophilic 
fibrillary matrix (Figure 2a). There was also pali-
sading necrosis (Figure 2b) and vascular prolifera-
tion (Figure 2c). A diagnosis of Governing Body 
Documentation - World Health Organization (GB 
WHO) grade IV was made. MR dorso-lumbar 
spine was done one month postoperatively, which 
shows spinal laminectomy and debulking of the 
tumor with reduced size and internal cystic 
changes. Additionally, the surgical gap was sealed 
by granulation tissue with no evidence of active 
infection or pseudo-meningocele formation. In 
turn, no further surgical procedures were per-
formed.
Postoperative Course
After confirmation of diagnosis, the patient 
underwent focal radiotherapy for the dorso-lum-
bar region (45Gy in 25 fractions/5 weeks) and con-
comitant temozolomide, then adjuvant therapy 
for six months. The patient was discharged and 
scheduled for regular follow-up at the outpatient 
oncology clinic. No side effects were detected dur-
ing the postoperative treatment.
In April 2017, follow-up MR dorso-lumbar 
spine with gadolinium (Gd) enhancement was 
done showing a stationary course of patient con-
dition with no new masses or lesion. Granulation 
tissue was seen creeping across the thecal sac; this 
tissue was inseparable from the CM as well as the 
distal thecal nerves (Figure 3). Regarding the neu-
rological status, no improvement was noticed in 
the motor weakness, and the patient was still con-
fined to the wheelchair.
During the postoperative follow-up period of 
15 months, local recurrence was detected on MR 
dorso-lumbar spine with Gd enhancement in the 
form of contrast-enhancing ill-defined soft tissue 
lesion in the spinal cord opposite to D10 down to 
L1 vertebral bodies. MRI brain with Gd was nor-
mal, and the patient was planned for palliative 
chemotherapy, but he refused.
DISCUSSION
Of all central nervous system tumors, prima-
ry spinal cord neoplasms account for only 2–4%, 
with the spinal GBM representing only 1.5% of all 
spinal cord tumors. Spinal cord GBM has an ag-
gressive course in which mortality usually results 
from cerebral metastases or complications of pro-
gressive spinal cord affection. With the introduc-
tion of temozolomide as an adjuvant therapy to 
surgery and radiotherapy, the overall survival 
rates have risen (7).
The review of literature done by Morais and 
his colleagues (4) summarizes the therapeutic op-
Figure 3: MR Dorso-lumbar spine with contrast Sagittal cuts, showing granulation tissue (arrow) 
creeping across the thecal sac and inseparable from CM and the distal thecal nerves.
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tions for spinal GBM. Some authors recommend 
focal spine radiotherapy and chemotherapy with 
temozolomide, others recommend additional 
whole-brain radiation even in the absence of intra-
cranial dissemination, while few authors suggest 
co-administration of intrathecal interferon-β and 
focal spine radiotherapy. Due to the absence of a 
consensus between studies regarding the thera-
peutic regimen in addition to the limited data 
available, the treatment regimen in our case con-
sists of total cordectomy and chemoradiotherapy.
Marchan and his colleagues (8), strongly rec-
ommend surgery as a reasonable option when the 
lesion is in the lower lumbar spine or sacral seg-
ments and also in patients with concomitant com-
plete paraplegia and sensory loss to prevent dis-
ease dissemination from the original cord lesion. 
According to their conclusion and our patient 
clinical scenario, we proceeded with total cordec-
tomy. However, complete resection without caus-
ing significant neurological deficit remains practi-
cally impossible.
In Singh and his colleagues (5) study, the ad-
dition of whole-brain radiotherapy as a treat- 
ment option to spinal radiotherapy was explained 
to be due to the large size of the cervical lesion and 
juxtaposition of the tumor to the phrenic nerve 
 nucleus which rendered the surgery difficult and 
challenging. This was not the scenario in our case, 
so we proceeded with focal spine radiotherapy 
with temozolomide as an oral chemotherapeutic 
agent, which has been proved to reduce the tumor 
size (5).
Despite all of the above, aggressive therapeu-
tic measures, the overall survival remains short in 
these patients, ranging between 6 – 16 months (4) 
with a median overall survival of 15 months (8). In 
agreement with these results, our patient experi-
enced local recurrence 15 months postoperatively.
In the review of literature done by Strik and 
his colleagues (6) regarding the prognosis of all 
spinal GB cases, only two studies are similar to 
ours in which cases experienced local recurrence 
leading to mortality, while the rest of studies re-
ported meningeal seedling and/or cerebral metas-
tases as causes of mortality. Moreover, only 1/3 of 
the reported patients experienced long-term sur-
vival (over 18 months), but the median survival 
time remains similar to our case report (15 
months).
CONCLUSION
Primary dorso-lumbar GBM with the previ-
ous clinical characteristics is a rare finding. While 
most Spinal GBM cases and previous literature de-
scribe treatment with focal spine radiotherapy and 
chemotherapy, the novelty in our case is the treat-
ment with surgery (total cordectomy) and chemo-
radiotherapy which lead to a relatively longer over-
all survival. Despite the total cordectomy and 
chemoradiotherapy treatment, recurrence occurred 
within a short time and with poor prognosis.
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